2軒目は近所のバー」が送る

なんで注目されてるの?

尋常性乾癬に対するスキリージ(R)(リサンキズマブ)FDA承認に ...

et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab ...

欧州委員会、中等症から重症の尋常性乾癬の治療薬として、スキ ...

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase ...

【PRワイヤー】アッヴィ合同会社

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase ... ...

最近の注目ワード



jpp